{"title":"The Safety and Efficacy of JAK Inhibitors: Have We Found the Right Pathway?","authors":"Lei Wang, Yung-Heng Lee, Xin-lei Yang, Po-Cheng Shih, Jin-fang Gao, Li-yun Zhang","doi":"10.1111/1756-185X.70130","DOIUrl":null,"url":null,"abstract":"<p>Elderly patients with autoimmune diseases require long-term medication and physiotherapy, which also involves lifestyle modification. Ongoing follow-up and treatment lead to frequent consumption of healthcare resources, including outpatient visits, hospitalization, examinations, and medicines, putting financial pressure on patients and families. At the same time, the loss of patients' labor force has socioeconomic implications. Among drug therapies, Janus kinase (JAK) inhibitors are an important class of drugs that have shown significant efficacy in the treatment of autoimmune and inflammatory diseases. However, the issue of selectivity of these drugs has been a challenge in clinical application. Nonselective JAK inhibitors may lead to adverse events, including infections, hematologic alterations, cardiovascular and thrombotic risks, and possible malignancy risks, limiting their use. Nevertheless, the significance of selectivity in achieving effective treatment responses and minimizing adverse events remains uncertain.</p>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 5","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185X.70130","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Rheumatic Diseases","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/1756-185X.70130","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Elderly patients with autoimmune diseases require long-term medication and physiotherapy, which also involves lifestyle modification. Ongoing follow-up and treatment lead to frequent consumption of healthcare resources, including outpatient visits, hospitalization, examinations, and medicines, putting financial pressure on patients and families. At the same time, the loss of patients' labor force has socioeconomic implications. Among drug therapies, Janus kinase (JAK) inhibitors are an important class of drugs that have shown significant efficacy in the treatment of autoimmune and inflammatory diseases. However, the issue of selectivity of these drugs has been a challenge in clinical application. Nonselective JAK inhibitors may lead to adverse events, including infections, hematologic alterations, cardiovascular and thrombotic risks, and possible malignancy risks, limiting their use. Nevertheless, the significance of selectivity in achieving effective treatment responses and minimizing adverse events remains uncertain.
期刊介绍:
The International Journal of Rheumatic Diseases (formerly APLAR Journal of Rheumatology) is the official journal of the Asia Pacific League of Associations for Rheumatology. The Journal accepts original articles on clinical or experimental research pertinent to the rheumatic diseases, work on connective tissue diseases and other immune and allergic disorders. The acceptance criteria for all papers are the quality and originality of the research and its significance to our readership. Except where otherwise stated, manuscripts are peer reviewed by two anonymous reviewers and the Editor.